# VISUPRIME® Eye Drops

> **NCT05677685** · NA · COMPLETED · sponsor: **VISUfarma SpA** · enrollment: 78 (actual)

## Conditions studied

- Macular Degeneration, Age Related
- Myopic Choroidal Neovascularisation
- Proliferative Diabetic Retinopathy
- Diabetic Macular Edema
- Macular Edema of Right Retina (Diagnosis)

## Interventions

- **DEVICE:** VISUPRIME
- **DEVICE:** Placebo

## Key facts

- **NCT ID:** NCT05677685
- **Lead sponsor:** VISUfarma SpA
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-22
- **Primary completion:** 2024-01-23
- **Final completion:** 2024-01-23
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2024-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05677685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05677685, "VISUPRIME® Eye Drops". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05677685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*